PMC:7784786 / 11810-12054 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7784786","sourcedb":"PMC","sourceid":"7784786","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7784786","text":"Three patients with diagnosis of COVID-19 classified as critically ill (two) and severely ill (one) were included in an expanded access trial to receive itolizumab in addition to standard treatment (http://rpcec.sld.cu/trials/RPCEC00000311-En).","tracks":[{"project":"LitCovid-PubTator","denotations":[{"id":"412","span":{"begin":6,"end":14},"obj":"Species"},{"id":"414","span":{"begin":153,"end":163},"obj":"Chemical"},{"id":"415","span":{"begin":33,"end":41},"obj":"Disease"},{"id":"416","span":{"begin":56,"end":70},"obj":"Disease"}],"attributes":[{"id":"A412","pred":"tao:has_database_id","subj":"412","obj":"Tax:9606"},{"id":"A414","pred":"tao:has_database_id","subj":"414","obj":"MESH:C000597346"},{"id":"A415","pred":"tao:has_database_id","subj":"415","obj":"MESH:C000657245"},{"id":"A416","pred":"tao:has_database_id","subj":"416","obj":"MESH:D016638"},{"subj":"412","pred":"source","obj":"LitCovid-PubTator"},{"subj":"414","pred":"source","obj":"LitCovid-PubTator"},{"subj":"415","pred":"source","obj":"LitCovid-PubTator"},{"subj":"416","pred":"source","obj":"LitCovid-PubTator"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}]},{"project":"LitCovid-sentences","denotations":[{"id":"T108","span":{"begin":0,"end":244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T108","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PubTator","color":"#93ecc8","default":true},{"id":"LitCovid-sentences","color":"#ecae93"}]}]}}